| Timing | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Items | Eligibility confirmation | Enrollment and assignment | Baseline | Treatment phase | |||||||||||
Visita | 1 | Â | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | |
Week after treatment onseta | -4 | Â | 0 | 4 | 8 | 12 | 24 | 36 | 48 | 60 | 72 | 84 | 96 | 108 | |
Acquisition of informed consent | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Pregnancy testb, gender, and date of birth | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Smoking history, anamnesis, and complications | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Status of study drug intake | Â | Â | Â | X | X | X | X | X | X | X | X | X | X | X | |
Status of concurrent therapyc | X | Â | X | X | X | X | X | X | X | X | X | X | X | X | |
Commencement of dialysis | Â | Â | Â | X | X | X | X | X | X | X | X | X | X | X | |
Development of gouty arthritis | Â | Â | Â | X | X | X | X | X | X | X | X | X | X | X | |
Development of adverse events | Â | Â | Â | X | X | X | X | X | X | X | X | X | X | X | |
Height (second visit only), body weight, and BMI | Â | Â | X | Â | Â | Â | Â | Â | X | Â | Â | Â | Â | X | |
Blood pressure (systolic, diastolic) and pulse rate | Xd | Â | X | X | X | X | X | X | X | X | X | X | X | X | |
12-lead electrocardiogram | Â | Â | Xe | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Xf | |
Hematology blood chemistryg, and urinalysish | Xd | Â | X | X | X | X | X | X | X | X | X | X | X | X | |
Blood | Serum uratei and creatinine concentrations | Xd |  | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
 | T-C, HDL-C, and TG |  |  | √ at fasting |  |  |  |  |  |  |  |  |  |  |  |
 | HbA1c | Xj |  | √ |  |  |  |  |  | √ |  |  |  |  | √ |
 | Markersk |  |  | √ |  |  |  |  |  | √ |  |  |  |  | √ |
Urine | Urinary creatinine, albumin, and uratei concentrations |  |  | √ |  |  |  |  |  | √ |  |  |  |  | √ |
 | Markersk |  |  | √ |  |  |  |  |  | √ |  |  |  |  | √ |
Blood sampling volume for measurement at the central laboratory (mL) | Â | Â | 16 | 10 | 10 | 10 | 10 | 10 | 16 | 10 | 10 | 10 | 10 | 16 |